ライフサイエンスコーパス: seroconversion

1 was humoral immunogenicity (anti-CTH522 IgG seroconversion).

2 ars, most of whom had HI titers <40 prior to seroconversion.

3 -COVID-19 serum samples, we confirmed autoAb seroconversion.

4 or neuraminidase inhibition (NAI) titers for seroconversion.

5 ericidal activity and longer protection from seroconversion.

6 ivary antigen blood type was associated with seroconversion.

7 ollow-up were classified as having undergone seroconversion.

8 .6 for virologic suppression to 17 for HBeAg seroconversion.

9 48 weeks of follow-up) with persistent HBsAg seroconversion.

10 eline, 482 (98%; 95% CI, 96 to 99) underwent seroconversion.

11 es infected with SHIV received CAB-LA before seroconversion.

12 ethral T. pallidum shedding can occur before seroconversion.

13 revalent or incident HSV-2 infection and HIV seroconversion.

14 significantly associated with delayed HBeAg seroconversion.

15 ear cells (PBMCs) and sigmoid biopsies after seroconversion.

16 persistent high-level shedding, viremia, and seroconversion.

17 of suicidal attempt in a woman following HIV seroconversion.

18 p<0.0001) in the past 6 months predicted HIV seroconversion.

19 y expanded CD8(+) T cells was observed after seroconversion.

20 not hepatitis B surface antigen clearance or seroconversion.

21 ine aminotransferase normalization and HBeAg seroconversion.

22 ore they developed detectable parasitemia or seroconversion.

23 Viral pathogens were associated with lower seroconversion.

24 enza (LCI) rates and factors associated with seroconversion.

25 endently associated with shorter time to HCV seroconversion.

26 near mixed model and estimated the time from seroconversion.

27 relatively long delay between infection and seroconversion.

28 GI, PGII and PGI:PGII levels and vibriocidal seroconversion.

29 had one or more FPIR results available after seroconversion.

30 ined as RTPCR+ influenza-like-illness and/or seroconversion.

31 HIV incidence was estimated from observed seroconversions.

32 estimate based on prospectively observed HIV seroconversions.

33 annual blood testing identifies subclinical seroconversions.

34 cores and assessed their ability to identify seroconversions.

35 factors to predict the one-year risk of HIV seroconversion: (1) membership in >=1 known "Risk Group"

36 ared with Cal09), along with improvements in seroconversion (24 of 126 [19%, 13.2-26.8]; p=0.011) and

37 Of these seroconversions, 29% (33/115) occurred in the periconcep

38 omes were seroprotection (HI titre >=40) and seroconversion (4-fold titre rise) rates and secondary o

39 Only secretor status was associated with seroconversion: 41% seroconversion for secretors vs 13%

40 were more likely than adults to show NA-only seroconversion (88% [0 to 4 yo] and 75% [5 to 19 yo] ver

41 In the immunogenicity subgroup, seroconversion (a Vi IgG level that at least quadrupled

42 any detectable HPV at the visit prior to HIV seroconversion (adjusted odds ratio, 1.02; 95% confidenc

43 HBV genotype C (hazard ratio = 4.40), HBeAg seroconversion after 18 years of age (hazard ratio = 2.4

44 Seroconversion after 2 IPV doses in each arm were as fol

45 0.59 years), and 75 subjects developed HBeAg seroconversion after antiviral therapy.

46 We have assessed seroconversion after routine vaccination with the pentav

47 after the 1(st) OCV dose; with no additional seroconversion after the 2(nd) dose.

48 [CrI] 0.009-0.15) and the risk ratio (RR) of seroconversion after three doses of bivalent OPVs was 0.

49 model, this is the first study demonstrating seroconversion against different L1 isoforms during the

50 Furthermore, we show no seroconversion against NiV glycoprotein and a lack of vi

51 We assessed seroconversion against poliovirus serotypes 1, 2, and 3,

52 The rVP1 ELISA detected seroconversion against SVA in clinically affected and no

53 onths, consistent with population-wide early seroconversion age.

54 e polymorphisms G428A, C302T, and A385T) and seroconversion among Indian infants who received a singl

55 We discovered that, prior to seroconversion, an early potent, largely type I interfer

56 included noninferiority of rubella antibody seroconversion and evaluating rotavirus IgA/IgG seroresp

57 Seroconversion and geometric mean titer (GMT) against HP

58 vere infections were associated with earlier seroconversion and higher peak IgM and IgG levels.

59 Primary endpoints were seroconversion and median antibody titres to type 2 poli

60 The evidence of similar seroconversion and safety with co-administered LJEV and

61 antibody titres at day 28 and percentages of seroconversion and seroprotection, all determined by hae

62 between antibiotic use in early life before seroconversion and the development of autoimmunity.

63 rses for several weeks followed by a delayed seroconversion and viral clearance.

64 lence and measles, rubella, and yellow fever seroconversion, and (1/3) log2 for log2-transformed anti

65 te-level analysis 44 sites (96%) reached 50% seroconversion, and 35 sites (75%) reached 80% seroconve

66 t day 2 and day 7, haemagglutinin inhibition seroconversion, and an increase in influenza haemaggluti

67 ested at seroconversion to IA, just prior to seroconversion, and during infancy.

68 peripheral T and B cell dysfunction, limits seroconversion, and enhances cellular antiviral immunity

69 duce severity of liver injury, achieve HBeAg seroconversion, and prevent development of liver fibrosi

70 dance, subsequent E. coli depletion prior to seroconversion, and T1D development.

71 ial contributor to reduced antirotavirus IgA seroconversion, and this interference was apparent after

72 By day 28, all the vaccine recipients had seroconversion as assessed by an enzyme-linked immunosor

73 -26) and, in 20 (87%) of 23 women, prevented seroconversion, as shown with western blotting.

74 Although seroconversion at 10 weeks did not meet significance in

75 come was based on the difference in rates of seroconversion at Day 210 (lower bound 95% CI > - 4%).

76 e sex with men showed fair prediction of HIV seroconversion (AUC, 0.701).

77 s 4-6 weeks post-vaccination and the rate of seroconversion between baseline and post-vaccination ser

78 ive outcomes such as pathogen incrimination, seroconversion, biomarkers, and anthropometry can be hel

79 roconversion, and 35 sites (75%) reached 80% seroconversion, by age 18, with significant heterogeneit

80 ACPA) was significantly higher - without any seroconversion, Chikungunya IgG and IgM levels were high

81 a A viruses were more likely to show NA-only seroconversion compared to children (56% versus 14% [5 t

82 PEVs were associated with a reduction in OPV seroconversion, consistent across species (odds ratio [9

83 he incidence of HIV on the basis of observed seroconversion data, participant-reported use of ART, pa

84 dies per intervention category and available seroconversion data.

85 based on the time interval between estimated seroconversion dates.

86 cluding antirotavirus immunoglobulin A (IgA) seroconversion (defined as the appearance of serum antir

87 s obtained every 6 months were evaluated for seroconversion, defined as a 4-fold increase in immunogl

88 The main study outcome was seroconversion, defined as convalescent antibody titres

89 individual- and country-level predictors of seroconversion (dichotomous) and antibody titer (continu

90 sessed in this study in early life or before seroconversion did not influence the risk of developing

91 her overall vaccine virus fecal shedding nor seroconversion differed by HBGA phenotype.

92 In high child mortality settings, seroconversion dramatically reduced the risk of severe r

93 ants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.

94 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1

95 HBeAg seroconversion during childhood predicts a lower risk of

96 children were associated with delayed HBeAg seroconversion during long-term follow-up, and more HBV

97 ntly increased rates of HBsAg loss and HBsAg seroconversion during therapy and functional cure after

98 rate between 2012 and 2017, from 4.0 to 2.3 seroconversion events per 100 person-years.

99 Primary infection was diagnosed based on seroconversion for HCMV and/or HCMV immunoglobulin M-pos

100 Cases and asymptomatic shedders showed seroconversion for IgG (80%), IgA (78%), and blockade an

101 the proportion of infants with IgG antibody seroconversion for measles 6 weeks after vaccination, an

102 individuals meeting the primary endpoint of seroconversion for poliovirus types 1, 2, and 3 was alre

103 The primary outcome was seroconversion for poliovirus types 1, 2, and 3 with tit

104 the proportion of infants with IgG antibody seroconversion for rubella 6 weeks after vaccination.

105 similar antibody ontogenies and patterns of seroconversion for S1, N, M, and WV antigens.

106 atus was associated with seroconversion: 41% seroconversion for secretors vs 13% for nonsecretors; re

107 In groups 1, 2, and 3, the IgA seroconversion frequencies among participants with IgA l

108 A third dose of HRV resulted in increased seroconversion frequencies and GMCs, compared with 2 dos

109 s (faeces and plasma) collected before or at seroconversion from 45 case children with IA and 48 matc

110 Vaccine response was defined as seroconversion from seronegative (<1:8) at baseline to s

111 Immune response was defined as seroconversion from seronegative (<1:8) at baseline to s

112 d serum antirotavirus immunoglobulin A (IgA) seroconversion (>/=20 U/mL) and geometric mean concentra

113 Vibriocidal antibody seroconversion (>= fourfold increase 14 days following a

114 2.46), and lamivudine therapy prior to HBeAg seroconversion (hazard ratio = 1.42) were predictors of

115 Seroconversion (IgA >= 20 U/mL) conferred substantial pr

116 titis within the past 12 months (symptomatic seroconversion illness or alanine aminotransferase > 10

117 Four (21%) reported a symptomatic HCV seroconversion illness, including 2 with jaundice.

118 PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95%

119 :CAF01 and CTH522:AH induced anti-CTH522 IgG seroconversion in 15 (100%) of 15 participants after fiv

120 Rate of seroconversion in 3AV (100%) was non-inferior to 1AV (97

121 th enterovirus detected at both time points (seroconversion in 44 of 127 infants [35%] vs 63 of 129 [

122 The algorithm detected seroconversion in 94% of individuals with a diagnosis of

123 VID-19) was 99% accurate in the detection of seroconversion in a blinded validation cohort of samples

124 the standard procedure in use for monitoring seroconversion in animals post vaccination, the prevalen

125 ns (SP) of the capsid can be used to monitor seroconversion in both infected and vaccinated animals.

126 h severe inflammation that facilitates HBeAg seroconversion in earlier life.

127 we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine in

128 ssay for the fluorescence-based detection of seroconversion in infected individuals from less than 1

129 llow fever vaccine was effective at inducing seroconversion in participants who were seronegative at

130 t documented seroconversion or of documented seroconversion in patients with a compatible clinical sy

131 0001), along with suboptimal serum antibody (seroconversion in six of 118 [5%, 1.9-10.7]) and T-cell

132 The main outcome of this study was HIV seroconversion in the intent-to-treat population as esti

133 6 weeks after vaccination, measles seroconversion in the measles-rubella plus LJEV group (4

134 ence -0.8% [90% CI -2.6 to 1.1]) and rubella seroconversion in the measles-rubella plus LJEV group (4

135 In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demons

136 We observed 1619 HIV seroconversions in 17 016 individuals, over 60 349 perso

137 ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person

138 the intervention group, 102 participants had seroconversion (incidence density 18.45 per 100 person-y

139 CTH522:CAF01 showed accelerated seroconversion, increased IgG titres, an enhanced mucosa

140 to a family member with T1D, autoantibody at seroconversion, INS gene (rs1004446_A), and non-HLA gene

141 esting and awareness of atypical patterns of seroconversion is highly recommended.

142 tion of chronically infected patients (i.e., seroconversion) is usually associated with increased HBV

143 Seroconversion may be more likely after exposure at nonk

144 Seroconversion measured by S1-ELISA occurred in 59 (86%)

145 ic factors to predict the 1-year risk of HIV seroconversion: membership in >=1 known "risk group" (eg

146 The primary study outcome was seroconversion (minimum titer of 1:40 and >/=4-fold rise

147 k Group strategy correctly classified 58% of seroconversions, Model-based 68%, and Machine Learning 7

148 ed to have LB by skin biopsy culture (N=18), seroconversion (N=2) or both (N=8).

149 Seroconversion occurred after 7 days in 50% of patients

150 Seroconversion occurred at a median of 12.5 days (IQR 9-

151 IgG seroconversion occurred between day 0 and day 21.

152 after positive results, including 88 in whom seroconversion occurred during follow-up.

153 Type 2 seroconversion occurred in 19 of 198 infants (9.6%, 95%

154 Spontaneous HBeAg seroconversion occurred in 359 subjects at a median age

155 Antipertussis toxin IgG seroconversion occurred in 9 out of 19 colonized partici

156 Anti-pertussis toxin IgG seroconversion occurred in nine out of 19 colonised part

157 If a seroconversion occurred in the HIV-negative partner, ano

158 All seroconversions occurred during the first 2 weeks after

159 29% (33/115) of seroconversions occurred in the periconceptional period

160 Eight HIV seroconversions occurred overall, with four documented d

161 day 7 was independently associated with both seroconversion (odds ratio 12.69, 95% CI 4.1-43.6; p<0.0

162 fter an MMR vaccine booster dose, we noted a seroconversion of 74% of seronegative HCWs.

163 516 individuals in 21 studies to reveal that seroconversion of both IgG and IgM occurs around 12 days

164 al Inaba vaccine strain CVD 103-HgR, elicits seroconversion of vibriocidal antibodies (a correlate of

165 There were no seroconversions on PrEP and 7 virological failures on ea

166 The primary end point was seroconversion or a >/=4-fold rise in antibody titer.

167 eduction neutralization test or detection of seroconversion or a 4-fold rise in virus-specific IgM or

168 nce of erythema migrans and documentation of seroconversion or a positive real-time blood PCR.

169 In children who presented seroconversion or developed T1D, we observed an increase

170 red the infection, achieving either anti-HBs seroconversion or hepatitis B surface antigen (HBsAg) lo

171 sence of erythema migrans without documented seroconversion or of documented seroconversion in patien

172 of circulating HBsAg, via either spontaneous seroconversion or therapeutic monoclonal antibodies, as

173 acquired brucellosis (LAB) were followed; no seroconversions or LAB cases occurred.

174 independently associated with higher odds of seroconversion (OR 4.3, 95% CI 1.2-14.9, p=0.02).

175 and lack of rotavirus immunoglobulin A (IgA) seroconversion (OR, 1.95; P = .018) were associated with

176 usly documented and describe the dynamics of seroconversion over the full course of the first wave of

177 elow 1 IU/mL (P < .001 vs control) and HBsAg seroconversion (P = .046 vs control).

178 tibody was the first-appearing indication of seroconversion [P = 0.006]) were statistically significa

179 ommercially available kits and verified with seroconversion panels, the WHO HBeAg standard, rHBeAg, a

180 We found an atypical seroconversion pattern, with initially only gp160 antibo

181 We report an incidence of 30.07 seroconversions per 100 child-years.

182 n during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with

183 on during 917 person-years of follow-up (6.1 seroconversions per 100 person-years).

184 The seroconversion percentages were significantly higher at

185 After seroconversion, perforin expression was downregulated in

186 bstudy compared oral rotavirus vaccine (RVV) seroconversion (primary outcome), and seropositivity and

187 In low child mortality settings, seroconversion provided near perfect protection against

188 Seroconversion provides an informative threshold for ass

189 The median time to seroconversion ranged from 10.3-11.0 days for these 3 as

190 The overall seroconversion rate after a second dose (booster) was 93

191 riority were predefined as <5% difference in seroconversion rate and <2-fold difference in geometric

192 force of infection among children using the seroconversion rate and examined how it varied geographi

193 nstrated the potential of using altitude and seroconversion rate as measures of malaria transmission

194 ncluded if the lower two-sided 90% CI of the seroconversion rate difference between IPV-Al and IPV wa

195 Their seroconversion rate reached 100% (97.5% confidence inter

196 The primary was seroconversion rate to each of the vaccine strains in th

197 The HIV seroconversion rate was 6.4 (95% CI: 1.3-18.7) per 100 p

198 The cumulative HBeAg seroconversion rate was significantly lower in the vacci

199 For AMA-1, the seroconversion rates (SCRs) ranged from 0.121 (Ngodhe) t

200 at baseline, anti-rotavirus immunoglobulin A seroconversion rates after 3 vaccine doses differed sign

201 ly with rotavirus vaccine, reduces rotavirus seroconversion rates after the first rotavirus dose with

202 High seroprotection and seroconversion rates against all influenza strains can b

203 rHA vaccine elicited the highest titers and seroconversion rates against all strains tested.

204 d increase against influenza B and (2) lower seroconversion rates against influenza H1N1 than noncolo

205 ferior to the 3D_M0,1,6 schedule in terms of seroconversion rates and 3D/2D geometric mean titers for

206 ion experienced (1) lower seroprotection and seroconversion rates and lower hemagglutination-inhibiti

207 inferiority were hemagglutination inhibition seroconversion rates and postvaccination geometric mean

208 Seroprotection and seroconversion rates are not well understood for 2-dose

209 Annual seroconversion rates based on a sero-catalytic model tha

210 Seroconversion rates for poliovirus types 1 and 3, respe

211 In the analysable population, seroconversion rates in mothers 1 month after the final

212 doses of bOPV or tOPV elicited type 1 and 3 seroconversion rates of at least 97.7%.

213 lok and Fluzone High-Dose recipients, though seroconversion rates trended higher in Flublok recipient

214 lok and Fluzone High-Dose recipients, though seroconversion rates trended higher in Flublok recipient

215 In groups receiving adjuvanted formulations, seroconversion rates were >/=85.7%, seroprotection rates

216 Seroconversion rates were 16.7%, 41.7%, and 13.3%, respe

217 Seroconversion rates were especially low in those on MMF

218 desh, rotavirus-specific plasma IgA antibody seroconversion rates were higher among infants of matern

219 Seroconversion rates were lower following MDA and serore

220 the modified intention-to-treat population, seroconversion rates were significantly higher in the bo

221 uals from northeast Tanzania using altitude, seroconversion rates, and parasite rates as proxies of h

222 Seroconversion rates, based on antibody prevalence to Pl

223 Seroconversion rates, GMT and GMR, number of ILI or LCIs

224 002), and diagnosis of maternal infection by seroconversion rather than avidity (AOR, 3.3; P = .007).

225 .2), and diagnosis of maternal infection via seroconversion rather than avidity (P=0.007, AOR=3.3).

226 nd that higher vaccine inoculum improved OCV seroconversion (RR 1.12, 95% CI 1.00-1.26).

227 ce that separating RVV and OPV increased RVV seroconversion (RR 1.21, 95% CI 1.00-1.47) and that high

228 rance/loss (RR = 1.9, 95% CI 1.7-3.1), HBeAg seroconversion (RR = 2.1, 95% CI 1.3-3.5), alanine amino

229 uppression (RR = 2.9, 95% CI 1.8-4.6), HBeAg seroconversion (RR = 2.1, 95% CI 1.4-3.3), and hepatitis

230 ables including comorbidities and time since seroconversion, significant, direct negative effects of

231 tion of samples collected >2 years after HCV seroconversion that were misclassified as recent; (3) sa

232 PrEP effectiveness should account for HIV seroconversion, the variable risk of HIV infection (seas

233 k-group strategy correctly classified 58% of seroconversions, the model-based strategy 68%, and machi

234 BeAg) or hepatitis B surface antigen loss or seroconversion; the numbers needed to treat ranged from

235 the first pretreatment CD4 count to time of seroconversion through a linear mixed model and estimate

236 Our results show that seroconversion to a salivary molecule, rLinB-13, is a ma

237 Percentage of seroconversion to all (ID 14% vs IM 15%; P = .8) or at l

238 time from human immunodeficiency virus (HIV) seroconversion to antiretroviral therapy (ART) initiatio

239 The median time from estimated seroconversion to ART initiation decreased by 42% from 6

240 The median time from estimated seroconversion to ART initiation decreased by 42% from 6

241 We estimated the time from HIV seroconversion to ART initiation in a population-based s

242 The estimated time from seroconversion to ART initiation was reduced in tandem w

243 Seroconversion to at least one of the influenza A or B v

244 ppression of HIV-1 by ART during AHI impedes seroconversion to biomarkers of infection, limiting the

245 ies in our labs have shown that a Th1-biased seroconversion to both rabies virus and MARV glycoprotei

246 = 370) were clustered, and progression from seroconversion to clinical diabetes within 5 years range

247 near mixed model and estimated the time from seroconversion to diagnosis and ART initiation.

248 e to ART initiation, the time from estimated seroconversion to diagnosis decreased by 28%, from a med

249 The time from estimated seroconversion to diagnosis decreased by 28%, from a med

250 ased to a median of 0.2 years, the time from seroconversion to diagnosis was 3.3 years among people d

251 iation decreased to 0.2 years, the time from seroconversion to diagnosis was 3.3 years among people d

252 Seroconversion to each poliovirus type was seen in 100%

253 Seroconversion to HA was more frequent in those <20 year

254 Seroconversion to heterologous A/H3N2, for example, was

255 Seroconversion to HPV 6, 11, 16, and 18 occurred in 83%,

256 asma metabolites with outcomes was tested at seroconversion to IA, just prior to seroconversion, and

257 Seroconversion to NA was not influenced by age or virus

258 Seroconversion to NAI alone was higher among children ag

259 Additionally, patients who showed early seroconversion to neutralizing IgG responses had better

260 The enhanced seroconversion to oral cholera vaccine CVD 103-HgR among

261 weeks after vaccination with mIPV2HD or IPV, seroconversion to poliovirus type 2 was recorded in 107

262 IgG titers in pre-dose 1 sera of infants and seroconversion to RV1 post-dose 1.

263 H led to modest but significant increases in seroconversion to RVV in rural Zimbabwean infants.

264 Seroconversion to RVV was significantly increased by del

265 umoral immunity (neutralising antibodies-ie, seroconversion) to all three serotypes and intestinal im

266 embrane fatty acids following birth until IA seroconversion under a nested case-control design.

267 /mL or lower in 24/40 participants (all with seroconversion up to 233,055 mIU/mL).

268 We evaluated antirotavirus immunoglobulin A seroconversion ('vaccine take") among 166 Ghanaian infan

269 c performance, to estimate rates of antibody seroconversion, viable metacestode acquisition, and sero

270 every visit, 2 had low concentrations at the seroconversion visit, and 1 had variable concentrations.

271 Seroconversion was 100% in Vi-TT and 88.6% in Vi-PS part

272 The weighted probability of durable HBeAg seroconversion was 91.9% and 88.0% at 12 and 24 months,

273 tibody titre by PRNT60 was 250 (176-355) and seroconversion was 95.7% (85.5-98.8).

274 dpoint titre was 1624 (95% CI 1146-2302) and seroconversion was 95.7% (95% CI 85.5-98.8); the geometr

275 dogs were inoculated with B. turicatae, and seroconversion was confirmed by the rBipA (recombinant B

276 Rotavirus seroconversion was defined as a 4-fold rise in immunoglo

277 0-neutralizing activity, the timing of RhCMV seroconversion was delayed by an average of 12 weeks.

278 4 weeks (RR 1.37, 95% CI 1.16-1.62) and OPV seroconversion was increased with monovalent or bivalent

279 However, vibriocidal antibody seroconversion was markedly higher among H. pylori serop

280 Seroconversion was observed in 32.8% (95% CI 24.7-41.9%)

281 e good, and the tolerance was acceptable; no seroconversion was observed.

282 No HIV seroconversion was reported during the 206 person-years

283 the subgroup of patients 18 to 64 years old, seroconversion was significantly greater with adjuvanted

284 Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidence in

285 After accounting for the time to seroconversion, we estimated that for every reported con

286 Lower serum zinc level and lack of IgA seroconversion were associated with increased risk of RV

287 Risk factors for seroconversion were frequency of injection, homelessness

288 Of these, 145 HIV seroconversions were observed, resulting in a weighted H

289 4,427 person-years; among these persons, 931 seroconversions were observed.

290 Eighteen HCV seroconversions were reported for an incidence of 19.4/1

291 with or without hepatitis B surface antibody seroconversion, which is associated with improved clinic

292 fects, so we only present pooled estmates on seroconversion, which were at least 80% for serotype 1 a

293 coupled with clinical data and assessment of seroconversion, will facilitate differentiation of actua

294 re than twice daily" was associated with HCV seroconversion with an adjusted odds ratio of 5.8 (95%CI

295 Seroconversion with fIPV im was noninferior to fIPV id f

296 The improvement in pH1N1 seroconversion with NY15 was even greater in children wh

297 Type 2 seroconversion with one dose IPV in Arm A was 72.0% (95%

298 onally, relatively few subjects demonstrated seroconversion with testing of convalescent-phase sample

299 with a trend toward a reduced risk of HSV-2 seroconversion, with an unadjusted hazard ratio (HR) of

300 upper limit of normal) or anti-HCV antibody seroconversion within 18 months.